Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study
- 1 September 2011
- journal article
- research article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 122 (3), 495-500
- https://doi.org/10.1016/j.ygyno.2011.05.040
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancerThe Lancet Oncology, 2008
- Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non–Small-Cell Lung Cancer Patients Treated With Cetuximab and ChemotherapyJournal of Clinical Oncology, 2008
- Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinomaGynecologic Oncology, 2007
- Analysis of chromosomes 3, 7, X and the EGFR gene in uterine cervical cancer progressionEuropean Journal Of Cancer, 2004
- Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor ReceptorJournal of Clinical Oncology, 2004
- Epidermal growth factor receptor-targeted therapy in colorectal cancerSeminars in Oncology, 2002
- Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasiaSeminars in Oncology, 2002
- EGFR and cancer prognosisEuropean Journal Of Cancer, 2001
- Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancerThe Lancet, 1997
- Epidermal Growth Factor Receptor Family and ChemosensitizationJNCI Journal of the National Cancer Institute, 1997